ENTA - Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the European Commission has approved MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy, for the treatment of acute HCV infection without cirrhosis or with compensated cirrhosis in adults and children aged 3 years and older.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced it is advancing zelicapavir into a registrational Phase 2b/3 clinical trial in adults at high risk of severe outcomes from RSV infection after a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The Phase 2b portion of the trial will confi.
[url="]Enanta Pharmaceuticals, Inc.[/url] (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 11:40 a.m. ET in New York, NY. A live w.
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $1.06 per share a year ago.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2026. “Since the inception of our immunology portfolio targeting type 2 diseases, our team has worked diligently to advance highly selective inhibitors of KIT, STAT6 and MRGPRX2 designed to enable convenient or.
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation highlighting zelicapavir and two posters with data on EPS-3903, a novel, potent and selective oral STAT6 inhibitor, at the American Thoracic Society (ATS) International Conference 2026 being held May 15-20, 2026 in Orlando, Fl.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the first participant has been dosed in a Phase 1 clinical trial of EDP-978, an oral, once-daily KIT inhibitor in development for urticaria and other mast cell-driven diseases. The Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial wil.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data on zelicapavir, an oral, once-daily, N-protein inhibitor, in development for the treatment of (RSV) have been accepted for two oral presentations at the European Society of Clinical Microbiology & Infectious Diseases Global 2026 (ESCMID) being held April 17-21.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA - Get Free Report) passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $12.73 and traded as low as $12.61. Enanta Pharmaceuticals shares last traded at $13.14, with a volume of 112,824 shares. Analysts Set New Price Targets Several equities analysts
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data from the Company's STAT6 inhibitor program will be presented in four posters at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists (AAI), being held April 15-19, 2026 in Boston, MA. Details of the presentations are as foll.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that members of management will participate in a fireside chat at The Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 10:45 a.m. ET in Miami Beach, FL. A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “.
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company's KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeti.
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $1.05 per share a year ago.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal first quarter ended December 31, 2025. “Enanta entered the year with significant momentum, advancing our leading RSV treatment portfolio with preparation for a Phase 3 study and expanding our immunology pipeline with the introduction of our.
KalVista Pharmaceuticals (NASDAQ: KALV - Get Free Report) and Enanta Pharmaceuticals (NASDAQ: ENTA - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings. Insider and Institutional Ownership 95.0% of Enanta
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average twelve-month